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1. Introduction 
Chronic myelogenous leukemia (CML) is characterized by the Philadelphia chromosome 
(Ph), which is originated by a balanced translocation between chromosomes 9 and 22, that 
is, t(9;22)(q34;q11) results in production of a BCR-ABL1 fusion protein with constitutive Abl 
kinase activity. In experimental models, the expression of said activity causes expansion of 
pluripotent stem cells, preferentially favours myeloid lineage differentiation, and inhibits 
erythroid  differentiation [1,2]. 
The BCR/ABL1 fusion in 22q11 is observed in ~95% of patients with chronic myeloid 
leukemia (CML). The BCR/ABL1 fusion signal on the derivative chromosome 22 is present 
in most CML patients. 
 In 5-10% of cases, this signal is generated by variant rearrangements (variant Ph) that 
involve other genomic regions [3-7]. More than 600 CML cases with variant rearrangements 
have been reported. The breakpoint distribution clearly exhibits a non-random pattern, with 
marked clustering to some chromosome bands, such as 1p36, 3p21, 5q13, 6p21, 9q22, 11q13, 
12p13, 17p13, 17q21, 17q25, 19q13, 21q22, 22q12, and 22q13, which suggests that these 
regions may be particularly prone to breakage. In addition, some specific variants are also 
known to be more frecuent, with the two translocations t(3;9;22)(p21;q34;q11) and 
t(17;22)(q25;q11) both having been reported in more than 10 cases [8].  
The occurrence of additional chromosomal aberrations (ACA) in Ph-positive CML is 
strongly associated with disease progression and has been interpreted as a sign of clonal 
evolution as well as chromosomal instability. Mitelman et al. [9] identified +Ph, +8, and 
i(17q) as the most common secondary changes that occur in nearly 90% of the cases with 
additional abnormalities. These three abnormalities were proposed to follow the ‘major 
route’ of clonal evolution, whereas other changes, which evolved more rarely, were 
suggested to follow the ‘minor route’ [9]; the terms ‘major’ and ‘minor’ refer to frequencies 
of the aberrations but not to the  pathogenetic impact. Thus the three major route changes, 
followed by +19, were the most common ACA. Other additional chromosomal 
abnormalities take place in less than 10% of the cases, the most frequent being –Y, +21, +17, 
–7, and –17. On the other hand, no apparent differences in ACA  between CML with 
standard Ph and CML cases with Ph variants are observed. The most common additional 
chromosomal changes are +8 (34%), +Ph (30%), i(17q) (20%), +19 (13%), –Y (8% of 
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anomalies), +21 (7%), +17 (5%), and –7 (5%), when these two CML groups are combined 
(Table 1). 
 
Chronic Phase 
(in order of appearance) 
Accelerated and Blastic Phase 
(in order of appearance) 
+Ph classical +Ph classical 
+Ph variant + Ph variant 
+ Ph, +8 +Ph, +8 
+Ph, -Y +Ph, -Y 
+Ph, -21 +Ph, i(17q) 
+8 +19/ +17 /-7 
Complex Karyotype Complex karyotype 
Table 1. Secondary chromosome abnormality patterns in CML patients. 
The chromosome bands frequently involved in secondary structural changes are similar in 
both groups. It is apparent that some chromosome segments are particularly ‘breakprone’: 
1q, 3q21, 3q26, 7p, 9p, 11q23, 12p13, 13q11–14, 17p11, 17q10, 21q22, and 22q10 when 
breakpoint distribution is observed in CML with standard Ph. 
The ACA are found in various combinations and it has been suggested that i(17q) followed 
by +8 are rather early changes, whereas trisomy 19 is a relatively late one [10,11]. Although 
this temporal order of ACA seems common, exceptions clearly exist. There are several 
examples of Ph-positive CML cases with +8 in all metaphases but i(17q) may also occur in 
only subclones, and Ph-positive CML cases  with a trisomy 19 [12]. Moreover, some 
combinations are more frequent than others. While +8, +Ph, and i(17q) often occur together, 
the combination i(17q),+19 (without +8/+Ph) has only been reported in 2 cases; 
+8,i(17q),+19 (without +Ph) in 16 cases; and i(17q),+19,+Ph (without +8) in 2 cases[12]. Some 
combinations (+8, i(17q); +8,+19; +19,+Ph) are positively associated, while i(17q),+19 and 
i(17q),+Ph are negatively associated according to Hashimoto et al. [13].  
Thus, the selective ACA appearance seems to vary, depending on other aberrations present 
in the combination. Furthermore, available data indicate that the most common secondary 
abnormalities occur in a step-wise, well-ordered manner, with a putative frequent pathway 
which starts with i(17q), then followed by +8 and +Ph, and lastly +19. Since three out of the 
four most frequent ACA involve gains, i.e. +8, +19, and +Ph, thus hyperdiploidy is the most 
common modal number in CML with ACA [14,15]; nearly 50% of the cases have 47–50 
chromosomes. Pseudodiploidy (46 chromosomes with structural abnormalities) is observed 
in almost 40% of the cases, while other modal numbers are uncommon. It is worth bearing 
in mind that the distributions of ploidy levels are not different between CML cases with 
standard Ph and those with variant Ph translocations, which confirms a strong indication 
that there are not any major differences between these two groups when related to 
cytogenetic evolution patterns. Most of the ACA in CML are genomically unbalanced, such 
as trisomies, monosomies, and deletions. In fact, this is common in hematologic 
malignancies, therefore while the primary changes have been proposed as balanced, the 
secondary changes are said to be unbalanced [16]. However, there are some notable 
exceptions in CML, in 10 cases the presence of t(15;17)(q22;q12–21) has been reported [12]. 
Other balanced rearrangements which are characteristically found in acute myeloid 
leukemia (AML) or myelodysplastic syndromes (MDS) and occasionally also found in CML 
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BC include: inv(3)(q21q26)/t(3;3)(q21;q26), t(3;21)(q26;q22), t(7;11)(p15;p15), t(8;21)(q22;q22), 
and inv(16) (p13q22) [12, 18-22].  
Although secondary by definition, these ACA do not behave as ordinary secondary 
changes. Firstly, they are strongly related to quite specific phenotypic features as the 
i(17q) have been associated with marked basophilia and the presence of pseudo Pelger-
Huët neutrophils [4], while other secondary aberrations are not. Secondly, they do not 
normally take place at the same time as other common additional changes, such as +8, 
i(17q), and +Ph, which clearly indicates that they follow a different evolutionary pathway. 
Rather than being secondary changes, they may be seen as second primary changes. It is 
worth noting that the fact that balanced aberrations characteristic of acute lymphoblastic 
leukemia (ALL), such as t(4;11)(q21;q23) and t(8;14)(q24;q32), have, to date, never been 
reported in CML blastic phase [12]. The idea that ALL-associated translocations cannot 
originate during the particular differentiation stage that characterizes the Ph-positive 
stem cell population is a possibility. On the other hand, and equally possible, ALL-
associated translocations may not provide any selective advantage for cells expressing the 
BCR/ABL1 chimeric protein.  
In 60–80% of the cases, ACA precede or accompany blastic phase [14, 15, 23-33], thus there is 
undoubtedly a strong association between secondary changes and transformation. 
Furthermore, early studies of splenic CML transformations give rise to strong support for 
the clinical importance of additional changes, showing that the secondary aberrations 
appeared in the spleen before bone marrow [34-36]. However, the prognostic impact of ACA 
has turned out to be difficult to assess. First, although most studies have reported that lack 
of ACA during blastic phase give rise to a better prognosis [32, 33, 37-41], some investigators 
have not found any prognostic differences between CML blastic phase cases with and 
without secondary changes [23, 30]. Second, it has been debated whether additional changes 
found during chronic phase constitute a dismal prognostic sign, announcing transformation. 
On one hand, as has been repeatedly highlighted, the emergence of new clones does not 
necessarily lead to disease progression and some clones appear only transiently [23, 42, 43]. 
On the other hand, the appearance of new ACA or increment of the clone with additional 
abnormalities has been shown to be  generally associated with clinical deterioration [28, 37, 
44].  
Moreover, Sokal et al. [45] reported that patients’ survival with secondary changes already 
present at the time of diagnosis had a shorter survival rate, but with survival curves for 
those with and without additional changes not diverging until after the 2-year point. Third, 
the number and types of aberrations present during chronic phase and blastic phase may 
also play a role. Quite often the karyotypic changes observed in the chronic phase are single 
events, particularly the loss of the Y chromosome, +8, +Ph, and i(17q) [47], while they are 
multiple and complex in blastic phase [15,31,37,42,46]. The aberrations in i(17q), or other 
changes that result in loss of 17p seem particularly ominous [15,23,25,37,42.47-49]. 
Furthermore, trisomy 8 and +Ph that take place in the blastic phase have been associated 
with poor prognosis [15, 50-52] (table 1). Thus, the prognostic impact of secondary 
abnormalities in CML is complex, heterogeneous, and is probably related to several 
parameters such as time of appearance and specific abnormalities [52]. 
Therefore, response to imatinib on the one hand, and resistance on the other, may also be 
conditioned by different types of ACAs. Enhanced response or resistance to treatment may 
be associated with the occurrence of different cytogenetic or molecular changes which are 
capable of activating the metabolic pathways with different outcomes [53,54]. Several 
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studies have assessed the impact of ACA on the clinical efficacy of imatinib by assuming 
that these abnormalities may confer BCR/ABL1-independent proliferation and decrease 
sensitivity to imatinib [50-55].   
However, the presence of additional copies of the BCR/ABL1 fusion onto structurally 
abnormal chromosomes has rarely been reported in the chronic or blastic phase of CML 
patients. 
We present two CML patients with additional copies of BCR/ABL1 fusions: the first patient 
with +Ph and BCR/ABL1 extra fusion in chromosome 18 in the blastic phase, and the 
second patient with four BCR/ABL1 fusion signals at diagnosis . 
2. Case report nº 1 
A 34-year-old patient was diagnosed with CML. The hematologic features were: Hb, 96 g; 
WBC, 354x109/L with 2% blasts, 4% basophils; platelets, 716x109/L. Neutrophil alkaline 
phosphatase (NAF) activity was absent. The bone marrow aspirate was hypercellular with 
1% blast cells.  
A cytogenetic study was performed on bone marrow cells and revealed a 
46,XY,t(9;22)(q34;q11) karyotype in all cells analyzed. FISH was performed on chromosome 
preparations using commercially available probe sets (LSI BCR/ABL-ES probe; Vysis, 
Downers Grove, IL) and based on a count of 100 cells (metaphases and interphases). The 
existence of the classic BCR/ABL1 fusion was proved. The patient was treated with 
hydroxyurea and a-interferon, with a satisfactory clinical, but unsatisfactory cytogenetic and 
FISH response , the maximum response reached,  based on a count of 120 cells, was 27/120 
cells with the BCR/ABL1 rearrangement during the 4 year follow-up . A bone marrow 
transplantation could not be performed because no compatible HLA-matched donor was 
available.  
After the aforementioned, 4 years after the initial diagnosis, a decrease of Hb, hematocrit, 
and platelets took place in the peripheral blood: WBC was 4.8x109/L with 38% blasts. Bone 
marrow was hypercellular, with 30% of cells representing the erythroid lineage at all the 
maturation stages, and with intense dyserythropoietic changes: 21% in the myeloid series 
(myeloid/erythroid ratio 5:1.5); 9% in the lymphoplasmocytoid series; and 40% as large 
blasts with fine chromatin in the nucleus, with two nucleoli, and irregularly shaped 
nongranular cytoplasms. Blast cells gave positive histochemical reactions for peroxidise and 
naphthol AS-D chloracetate esterase (inhibited by fluoride) and were periodic acid Schiff 
(PAS) positive as granules. Analysis in bone marrow of more than 100 cells at this time 
revealed that 94% of the cells had two fused BCR/ABL signals: one on the Ph chromosome 
and the other on the short arm of a derivative chromosome 18, detected by metaphase FISH 
analysis with Vysis LSI-BCR/ABL-ES and Cytocell mBCR/ABL probes (Fig. 1). Karyotype 
in bone marrow samples showed one Ph chromosome and one normal chromosome 22, and 
one normal chromosome 18 and another with a deletion of part of its short arm. The 
remaining 6% of cells only had the usual BCR/ABL1 fusion, without any other 
abnormalities.  
The patient was then treated with mitoxantrone and cytarabine without clinical response, 
and later with splenic radiotherapy, which led to an intense pancytopenia; the patient then 
died 4 years 8 months after the initial diagnosis. 
The occurrence of additional chromosome changes is an ominous sign, indicating that 
illness progression is imminent; however, the etiology of blastic transformation is still not 
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completely clear. Erythroblastic transformation of CML has been reported in 10% of patients 
in blastic crisis; nonetheless, this has not been clearly associated to specific chromosome 
aberrations [3-7, 61-66].  
 
 
(a)                                                                 (b) 
Fig. 1. (a) Metaphase cell FISH showing two fusions (a classic one in the Ph chromosome 
and another BCR/ABL fusion in 18p) (arrows), two orange signals (normal and residual 
ABL probe in 9q34), and one green signal (BCR in the normal 22 chromosome) (94% of cells). 
(b) Partial FISH metaphase with DAPI/ FITC showing the three copies of the BCR gene (in 
the Ph chromosome; in 18p, indicated by arrows; and in the normal chromosome 22) (94% of 
more than 100 cells).  
Three cases have been described with additional BCR/ABL1 fusions onto 18p accompanied 
by other chromosome alterations [67, 68], two of which have been reported by the same 
authors [68]. In the case described by Tanaka et al. [67], the blast morphology was not 
specified. Khac et al. [68], however, described two patients with CML in blastic 
transformation with a duplication and transposition of BCR/ABL1 to 18p that presented 
loss of part of its short arm; both patients had erythroblastic transformations, which the 
authors believed to be associated with this particular cytological subtype of disease 
progression in CML. The present case supports the relationship suggested by Khac et al. [68] 
between a tendency for erythroblastic transformation and the presence of extra fused 
BCR/ABL1 onto 18p, as in the patient we described, with a duplication and transposition of 
BCR/ABL1 onto 18p in the majority line (95%) in blastic phase, with no other chromosome 
alterations, together with an increase of red cells, intense dyserythropoietic features and 
PAS in granules leading to a fatal outcome. 
3. Case report nº 2 
A 31-year-old caucasian man, a smoker (10 cigarettes/day) and with a past 
appendectomy, presented with a history of abdominal pain with diarrhea and an abscess 
in the jawbone; he was attended at the Department of Hematology. Clinical examination 
revealed hepatosplenomegaly. Complementary tests revealed leukocytosis in a peripheral 
blood examination. His white blood cell count was 52x109/L, with a peripheral 
monocytosis of 18x109/L and a left shift. The number of platelets was 94x109/L; 
hemoglobin was normal; leukocyte alkaline phosphatase was reduced. In the biochemical 
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study (which included lipids and thyroid hormones) increased HDL, vitamin B12 and uric 
acid were observed; findings of the remaining studies were normal. The 
thoracoabdominal computed tomography scan revealed mild bilateral axillary 
adenopathy, right pleural effusion, hepatomegaly, and periaortic adenopathy; the 
gastroduodenal endoscopy was unremarkable. The patient’s bone marrow was described 
as hypercellular, without visible fat spaces; megakaryocytes were present, normal in both 
number and morphology. The myeloid/erythroid ratio was 20:1. Myeloid precursors were 
high in number and left-shifted, with a relative increase in promyelocytes (7%) and 
eosinophils (6%). The blast percentage was 4%. Erythroid precursors were present in 
normal numbers.  
Cytogenetic analysis with G-banding was performed on chromosomes obtained from 24-
hour bone-marrow cell cultures following the standard procedures. Fluorescence in situ 
hybridization (FISH) was performed on chromosome preparations using a commercially 
available dual-color LSI BCR/ABL-ES probe (Abbott Molecular, Des Plaines, IL) labelled in 
SpectrumGreen and SpectrumOrange, respectively, to detect the BCR/ABL1 
rearrangements in interphase and metaphase nuclei. To identify the chromosomes 9 
correctly, a Vysis whole chromosome paint (WCP 9) was used, labeled in Spectrum- Orange. 
The hybridization was performed according to the manufacturer’s protocols.  
Molecular studies using real-time polymerase chain reaction (RT-PCR) from peripheral 
blood were performed. One microgram of the total RNA was used for cDNA synthesis, and 
later PCR was performed based on a Biomed protocol and using a LightCycler 2.0 [69] 
(Roche Diagnostics, Indianapolis, IN; Mannheim, Germany). A RT-PCR study with a 
fluorescence resonance energy transfer (FRET) probe quantification kit t(9;22) (Roche) that 
detected BCR/ABL1 fusion transcripts resulting from the major and minor breakpoint 
cluster regions (M-BCR and m-BCR) was also performed. The primers used in this kit were 
specifically designed to detect b3a2, b2a2, and e1a2 fusion transcripts, thereby covering 
>95% of the described t(9;22)  translocations. 
At diagnosis, cytogenetic studies indicated the following karyotype:  
46,XY,der(22)t(9;22)(q34;q11.2)[3]/48,XY,+9,t(9;22)(q34;q11.2)x2,+22[40] (figure 2A). 
FISH studies on 167 metaphase and interphase cells revealed the presence of a mosaicism 
formed by three distinct cellular clones at diagnosis. In the major clone, 150/167 cells (90%) 
presented four BCR/ABL1 fusion signals, with two signals on the two chromosomes der(9) 
and the other two signals on the two Ph chromosomes (Fig. 2B and 3). Three chromosomes 9 
were observed with a WCP-9 probe. A sole BCR/ABL1 fusion signal, on chromosome 22, 
was observed in 5/167 cells (3%), and there were no rearrangements in the remaining cells 
analyzed (12/167, or 7%). The FISH technique was performed twice, confirming the results. 
The RT-PCR demonstrated a p210, b3a2 fusion transcript.  
Once the patient was diagnosed as CML, treatment with imatinib was initiated at a dose 
of 400 mg/day. Two months later the patient was asymptomatic and in hematological 
remission. The b3a2 transcripts detected by RT-PCR were at 59%. The patient continued 
with the same imatinib treatment of 400 mg/day. Ten months after beginning therapy,  
a FISH follow-up study performed on a bone marrow sample revealed a cellular 
mosaicism, with partial remission. The initial majority line with four fusions was present 
in only 20/300 cells, only one BCR/ABL1 rearrangement was seen, on chromosome 22, in 
25/300 cells; the remaining 255/300 cells were normal, without any fusion signals. The 
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p210 BCR-ABL1 fusion transcript, identified using RT-PCR (Biomed protocol), decreased 
to 1.66%.  
 
 
Fig. 2. (A) Partial metaphase karyogram shows two derivative chromosomes 9 and two 
derivative chromosomes 22, along with one each of normal chromosomes 9 and 22 in case 
report nº 2 of chronic myeloid leukemia in chronic phase. (B) For the same patient, 
interphase FISH with LSI BCR/ABL-ES probes (Vysis; Abbott Molecular, Des Plaines, IL) 
shows four BCR/ABL1 fusion genes (arrows). Filter: 4’, 6-diamidino-2-phenylindole-
rhodamine-fluoresceinisothiocyanate 
A year after diagnosis, in a routine evaluation, the patient was still asymptomatic and in 
hematological remission. The RT-PCR study performed using FRET probes detected 
BCR/ABL1 transcripts. A quantification analysis (Biomed protocol) performed then was 
negative for p210 (b3a2), but p190 (e1a2) was found at 23.3%. Thus, the original sample was 
analyzed again, in which p190 was also positive. The original imatinib treatment was 
changed to dasatinib at 100 mg/day due to the disappearance of p210 and the presence of 
p190 in 23.3%. 
At diagnosis, the patient in the present case had a karyotype with 48 chromosomes and four 
BCR/ABL1 fusion signals distributed between the two Ph chromosomes and two out of the 
three chromosomes 9 in 90% of all the cells analyzed by FISH. One possible explanation 
could be that the classical BCR/ABL1 fusion occurs initially, followed first by the 
duplication and translocation of the fusion to a derivative 9 chromosome and then by a 
duplication of both Ph chromosomes and 9q+ (the remaining chromosomes were unaltered).  
The possible poor prognostic effect of a BCR/ABL1 fusion located on chromosome 9 has 
been described [4, 5, 61, 70]. Nevertheless, other researchers have reported cases of patients 
with a chimerical BCR/ABL1 fusion gene on chromosome 9 in ~80% of CML samples [62] 
and a double fusion on both chromosomes 9 [71, 72], and the clinical course of the disease 
seemed unaffected by the positional regulation. In the present case, there was only 
hematologic remission after treatment. With regard to treatment with imatinib, additional 
copies of the Ph chromosome have been reported [73, 74]. The development of additional 
chromosomal aberrations (ACA) in Ph negative or Ph+ cells during treatment is a sign of 
clonal evolution and of treatment failure. Patients with ACA more frequently tended to 
have BCR/ABL1 mutations (53% versus 29%) and more resistant mutations (60% versus 38%) 
[75]. The acquisition of ACAs may confer resistance to imatinib mesylate a mechanism for 
imatinib resistance. Therefore, response to imatinib on one hand and resistance on the other 
may also be conditioned by different types of ACAs. Enhanced response or resistance to 
treatment may be associated with the occurrence of different cytogenetic or molecular 
changes that are able to activate metabolic pathways with different outcomes [76-77]. 
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Fig. 3. Metaphase FISH with Vysis LSI BCR/ABLeES probes shows four BCR/ABL fusion 
signals (yellow): two signals on the two der(9) chromosomes and two signals on the two 
der(22) chromosomes. The green and orange signals indicate, respectively, the BCR gene on 
the normal chromosome 22 and the ABL gene on the normal chromosome 9.  
In the present case, all the cytogenetic aberrations began to decrease with imatinib 
treatment, and only a small percentage of cells maintained the initial karyotype.  
At the molecular level, the patient showed a p210 and p190 fusion. A p210 decrease 
coincided with an important partial cytogenetical remission of the four BCR/ABL1 fusions. 
During evolution of the disease, the p210 protein disappeared with imatinib as first-line 
treatment, but p190 increased until treatment with dasatinib was started. 
Five months after the start of treatment with dasatinib, RT-PCR showed that p210 remained 
negative and p190 had decreased to 1%. Two years after diagnosis, the patient was still 
clinically asymptomatic and hematologically in remission. New FISH studies, with 200 cells 
analyzed, also showed complete cytogenetic remission. Molecular studies remained 
negative for p210 and positive for p190 in only 0.09%.  
Although interphase FISH is increasingly used for BCR/ABL1 gene rearrangement 
identification in CML, we believe, in agreement with Lim et al. [72] and Primo et al. [79] and  
supported by the present case, that the exact interpretation of any atypical interphase FISH 
pattern is dependent on FISH metaphase studies and molecular breakpoint definition of 
BCR/ABL1 fusion.  
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